This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CI or HUM: Which HMO Stock is Better Placed at the Moment?
by Zacks Equity Research
Cigna (CI) and Humana (HUM) are well-positioned to expand in the promising HMO space. Let's try to find out which one fares better via comparative evaluation.
Cigna (CI) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
Cigna Group (CI) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group
by Zacks Equity Research
Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.
Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
EverQuote (EVER) Q1 Earnings Beat on Lower Operating Expenses
by Zacks Equity Research
EverQuote (EVER) expects total revenues of $70-$75 million for the second quarter of 2023.
Company News for May 8, 2023
by Zacks Equity Research
Companies in The News Are: ENB,CiHUN,PAA
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
Here's What Key Metrics Tell Us About Cigna (CI) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna (CI) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 3.44% and 2.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
American International Group (AIG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
American International Group (AIG) delivered earnings and revenue surprises of 13.99% and 9.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
This is Why Cigna (CI) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
Why Earnings Season Could Be Great for Cigna Group (CI)
by Zacks Equity Research
Cigna Group (CI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
Assurant (AIZ) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Assurant (AIZ) delivered earnings and revenue surprises of 55.11% and 2.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins
by Zacks Equity Research
Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins are included in this Analyst Blog.
Top Stock Reports for AMD, Cigna & Moderna
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Advanced Micro Devices, Cigna and Moderna.
Earnings Preview: Cigna (CI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $250.33, marking a +0.87% move from the previous day.
Cigna (CI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $252.12, marking a -1.43% move from the previous day.
Cigna (CI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cigna (CI) closed at $256.10 in the latest trading session, marking a -1.38% move from the prior day.
Investors Heavily Search Cigna Group (CI): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Cigna (CI) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cigna (CI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $263.81, marking a +1.17% move from the previous day.
Cigna (CI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $265.29, marking a -0.22% move from the previous day.